Axsome Therapeutics (AXSM) Total Debt (2016 - 2026)

Axsome Therapeutics' Total Debt history runs 11 years deep, the most recent figure standing at $129.0 million for Q1 2026.

• In Q1 2026, Total Debt fell 32.1% year-over-year to $129.0 million; the TTM figure through Mar 2026 stood at $129.0 million (down 32.1% YoY), while the FY2025 annual figure was $127.8 million, down 29.3% from the prior year.
• Total Debt came in at $129.0 million for Q1 2026 at Axsome Therapeutics, up from $127.8 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $190.0 million in Q1 2025 to a low of $49.3 million in Q1 2022.
• A 5-year average of $150.4 million and a median of $180.7 million in 2024 frame the typical range for Total Debt.
• Across the five-year window, Total Debt surged 211.51% in 2023 and plunged 32.32% in 2025, its largest moves.
• Axsome Therapeutics' Total Debt stood at $100.2 million in 2022, then soared by 84.18% to $184.5 million in 2023, then dropped by 2.04% to $180.7 million in 2024, then declined by 29.3% to $127.8 million in 2025, then rose by 0.97% to $129.0 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $129.0 million, $127.8 million, and $127.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison